Bausch Health Cos Operating Income 2012-2026 | BHC

Bausch Health Cos operating income from 2012 to 2026. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Bausch Health Cos Annual Operating Income
(Millions of US $)
2025 $1,813
2024 $1,546
2023 $963
2022 $454
2021 $450
2020 $676
2019 $-203
2018 $-2,384
2017 $102
2016 $-566
2015 $1,527
2014 $2,001
2013 $-410
2012 $80
2011 $300
Bausch Health Cos Quarterly Operating Income
(Millions of US $)
2026-03-31 $-950
2025-12-31 $474
2025-09-30 $619
2025-06-30 $444
2025-03-31 $276
2024-12-31 $558
2024-09-30 $318
2024-06-30 $389
2024-03-31 $281
2023-12-31 $362
2023-09-30 $14
2023-06-30 $412
2023-03-31 $175
2022-12-31 $-244
2022-09-30 $244
2022-06-30 $161
2022-03-31 $293
2021-12-31 $367
2021-09-30 $574
2021-06-30 $-270
2021-03-31 $-221
2020-12-31 $-5
2020-09-30 $460
2020-06-30 $-27
2020-03-31 $248
2019-12-31 $-1,076
2019-09-30 $329
2019-06-30 $257
2019-03-31 $287
2018-12-31 $25
2018-09-30 $117
2018-06-30 $-245
2018-03-31 $-2,281
2017-12-31 $-322
2017-09-30 $38
2017-06-30 $175
2017-03-31 $211
2016-12-31 $150
2016-09-30 $-863
2016-06-30 $81
2016-03-31 $66
2015-12-31 $167
2015-09-30 $448
2015-06-30 $342
2015-03-31 $571
2014-12-31 $605
2014-09-30 $684
2014-06-30 $355
2014-03-31 $357
2013-12-31 $224
2013-09-30 $-892
2013-06-30 $142
2013-03-31 $117
2012-12-31 $-98
2012-09-30 $29
2012-06-30 $87
2012-03-31 $61
2011-12-31 $-6
2011-09-30 $112
2011-06-30 $118
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.086B $10.266B
Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $35.437B 10.97
BridgeBio Pharma (BBIO) United States $14.460B 0.00
Dr Reddy's Laboratories (RDY) India $11.109B 17.29
Aspen Pharmacare (APNHY) South Africa $3.708B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.918B 22.33
Taysha Gene Therapies (TSHA) United States $1.290B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.924B 7.28
Personalis (PSNL) United States $0.630B 0.00
Assembly Biosciences (ASMB) United States $0.451B 0.00
Sol-Gel Technologies (SLGL) Israel $0.210B 0.00
Metagenomi Therapeutics (MGX) United States $0.052B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00